Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference

Business Wire December 4, 2019

Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer

Business Wire December 3, 2019

Advaxis Announces Business and Pipeline Update

Business Wire October 24, 2019

Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

Business Wire October 10, 2019

Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial

Business Wire October 7, 2019

Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update

Business Wire September 9, 2019

Advaxis, Inc. Issues Letter to Shareholders

Business Wire August 22, 2019

BriaCell Appoints Richard J. Berman to Board of Directors

GlobeNewswire August 12, 2019

Advaxis, Inc. Announces Closing of $17 Million Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option

Business Wire July 25, 2019

Advaxis, Inc. Announces Pricing of $16 Million Public Offering

Business Wire July 23, 2019

New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies

Business Wire July 15, 2019

Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study

Business Wire June 27, 2019

Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

Business Wire June 10, 2019

Advaxis to Host Business Update Conference Call on June 11, 2019

Business Wire June 4, 2019

FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac

Business Wire May 15, 2019

Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference

Business Wire May 14, 2019

Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer

Business Wire May 13, 2019

Advaxis to Participate in Five Upcoming Industry Conferences

Business Wire May 7, 2019

Advaxis Announces Pricing of Its Public Offering of Common Stock

Business Wire April 3, 2019

Advaxis, Inc. Announces Proposed Public Offering of Common Stock

Business Wire April 2, 2019